2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 208-210
This program is top science that showcases hot topics in platelet and megakaryocyte biology. It is balanced between both platelets and megakaryocytes and also a a broad array of topics. Male to Female representation was difficult, but we currently have one woman. Our first alternate is a woman and we suggest having woman moderators (we suggested two junior and two more senior).<br /><br />abs26-7483 was not chosen for an oral presentation due to concerns about lack of key information in the abstract that didn't allow the group to discern the impact of the findings.<br /><br />Backups<br />1. abs26-10358<br />2. abs26-13313<br />3. abs26-1646
Technology and Procedures, Assays, Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Thrombocytopenias, Infectious Diseases, Bacterial, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

470 Loss of platelet factor XIII-a is not associated with impaired platelet activation, aggregation, or contraction: Implications for managing factor XIII-a deficient patient in high-risk settings

Yaqiu Sang, PhD, Mya Merritt2, Kadri Kangro, PhD3, Stephanie Reitsma, PhD4, James Luyendyk5, Molly Mollica6, Nigel S. Key, MD7, Alisa Wolberg, PhD8
1 UNC Blood Research Center, Chapel Hill, North Carolina, United States, Unversity of North Carolina at Chapel Hill, Chapel Hill, NC, United States
2 University of Maryland, Baltimore County, Baltimore, Maryland, United States
3 UNC Blood Research Center, Chapel Hill, North Carolina, United States, Unversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
4 UNC Blood Research Center, Chapel Hill, North Carolina, United States, Unversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
5 Michigan State University, East Lansing, Michigan, United States
6 University of Maryland, Baltimore County, Baltimore, Maryland, United States
7 UNC Blood Research Center, Chapel Hill, North Carolina, United States, Unversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
8 UNC Blood Research Center, Chapel Hill, North Carolina, United States, Unversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Background: Protransglutaminase factor (F)XIII is present in plasma (FXIII-A2B2) and hematopoietic-derived cells (FXIII-A2) and represents ~3% and ~0.3-0.5% of the human and mouse platelet proteome, respectively. Approximately half of circulating FXIII-A is stored in platelets. Severe congenital FXIII-A deficiency is associated with increased risk of umbilical cord bleeding, intracranial hemorrhage, impaired wound healing, and recurrent spontaneous miscarriages. Administration of plasma-derived FXIII-A2B2 or recombinant FXIII-A2 to these patients reduces bleeding risk. However, controversial reports suggesting platelet FXIII-A is required for platelet function creates equipoise on the potential need for platelet transfusion for FXIII-A-deficient patients, especially in high-risk settings when higher FXIII activity may be needed.

Aim: Determine the contribution of platelet FXIII-A to platelet protein composition and hemostatic functions (integrin activation, degranulation, aggregation, and contraction).

Methods: We performed complementary experiments using whole blood, platelet-rich plasma (PRP), washed platelets, and platelet-poor plasma isolated from FXIII-deficient mice (F13a1-/- [complete loss of both plasma and platelet FXIII-A] and F13b-/- [<5% plasma FXIII-A but normal platelet FXIII-A]) and littermate controls. We also studied healthy human participants and a female FXIII-A-deficient patient with severe bleeding history (muscular, menorrhagia, and recurrent spontaneous miscarriages) seen at the UNC Hemophilia and Thrombosis Center for diagnosis and pregnancy management; this patient had a homozygous pathogenic mutation in F13A1 (c.782G>A, p.Arg261His), chromogenic FXIII activity <5 IU/dL, and complete loss of FXIII-A antigen in both plasma and platelets. Proteomic profiling of mouse platelets and plasma was performed by untargeted mass spectrometry. Mouse and human platelets or PRP were activated in the absence or presence of cell-impermeable or -permeable transglutaminase inhibitors. Integrin activation and P-selectin exposure were measured by flow cytometry, and aggregation by light transmission aggregometry. Single platelet and bulk clot contraction were measured by traction force microscopy and visually, respectively.

Results: Proteomic analysis of F13a1+/+ and F13a1-/- mouse plasma and washed resting platelets detected >650 and >5600 proteins, respectively; however, <1% of proteins significantly differed >1.5-fold between genotypes. Following activation with agonists targeting glycoprotein (GP)VI (convulxin), P2Y1/P2Y12 receptors (ADP), or protease-activated receptors (PAR-1 and PAR-4 peptides, thrombin), integrin αIIbβ3 activation, P-selectin exposure, and platelet aggregation did not differ between FXIII-sufficient versus FXIII-A-deficient or -inhibited mouse or human platelets or PRP. Likewise, single platelet contraction assays showed comparable contractile force in thrombin-activated FXIII-A-sufficient and -deficient mouse platelets, and that human platelets lacking FXIII-A are capable of contraction. Clot contraction triggered by a low concentration of thrombin was slightly delayed in FXIII-A-deficient, FXIII-A-inhibited, and FXIII-B-deficient mouse and human PRP; however, addition of plasma FXIII-A2B2 normalized clot contraction, collectively implicating plasma FXIII-A2B2 but not platelet FXIII-A in clot contraction dynamics. Administration of recombinant FXIII-A to the FXIII-A-deficient patient to maintain plasma trough FXIII-A2B2 levels >20% enabled a successful pregnancy and delivery via elective cesarean section.

Conclusions: Loss of platelet FXIII-A does not compromise key platelet hemostatic functions including activation, degranulation, aggregation, or contraction. Plasma FXIII-A2B2 is sufficient to support hemostasis in FXIII-A deficiency.

Yaqiu Sang, PhD: Hemab Therapeutics - Research Funding